Thursday, 25 February 2016

First Paper Published from IiME-funded Research

(See also for the latest news on the Rituximab trial

Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study


Summary

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a heterogeneous condition of unknown aetiology characterized by multiple symptoms including fatigue, post-exertional malaise and cognitive impairment, lasting for at least 6 months. Recently, two clinical trials of B cell depletion therapy with rituximab (anti-CD20) reported convincing improvement in symptoms. A possible but undefined role for B cells has therefore been proposed. Studies of the relative percentages of B cell subsets in patients with ME/CFS have not revealed any reproducible differences from healthy controls (HC). In order to explore whether more subtle alterations in B cell subsets related to B cell differentiation exist in ME/CFS patients we used flow cytometry to immunophenotype CD19+ B cells. The panel utilized immunoglobulin (Ig)D, CD27 and CD38 (classical B cell subsets) together with additional markers. A total of 38 patients fulfilling Canadian, Centre for Disease Control and Fukuda ME/CFS criteria and 32 age- and sex-matched HC were included. We found no difference in percentages of classical subsets between ME/CFS patients and HC. However, we observed an increase in frequency (P < 0·01) and expression (MFI; P = 0·03) of CD24 on total B cells, confined to IgD+ subsets. Within memory subsets, a higher frequency of CD21+CD38– B cells (>20%) was associated with the presence of ME/CFS [odds ratio: 3·47 (1·15–10·46); P = 0·03] compared with HC, and there was a negative correlation with disease duration. In conclusion, we identified possible changes in B cell phenotype in patients with ME/CFS. These may reflect altered B cell function and, if confirmed in other patient cohorts, could provide a platform for studies based on clinical course or responsiveness to rituximab therapy.

Monday, 15 February 2016

RELEASE THE PACE TRIAL DATA SAYS TYMES TRUST

Message from Jane Colby, Executive Director of the TYMES Trust

MAY BE REPOSTED

The letter that we sent to QMUL about the release of the PACE trial data has today been put on our public Facebook page here:


You do not need to be signed up to Facebook to read this.

As if there were not enough concerns about the PACE trial, we at Tymes Trust have the added concern, on behalf of parents and families of children with ME, that a children's version of PACE is being set up.

Please read our letter and spread the link widely.

Many thanks

Jane

Jane Colby
The Young ME Sufferers Trust

Tuesday, 9 February 2016

New documentary shines light onto CDC's cover-up of links between vaccines and autism



(NaturalNews) In 1971, the MMR vaccine against measles, mumps and rubella was licensed in the United States. Since then, it has been marketed in more than 60 countries around the world under various names such as M-M-R II, Priorix, Tresivac and Trimovax. As recommended by its developers, the first dose of the vaccine is administered to children around age one, while the second dose is administered between ages four and five.

Doubts about the MMR vaccine first became public in 1998, due to a paper published by the world-renowned gastrointestinal surgeon and researcher Andrew Wakefield. In his research, Dr. Wakefield observed that there is a link between the MMR vaccine and gastrointestinal conditions related to autism. He did not recommend that parents should reject the vaccine, but rather that a single vaccine rather than a combo should be implemented.

Now, a new documentary from critically acclaimed journalist Ben Swann exposes the CDC's dirty secrets for the whole world to see. Click here to watch the revealing video, "CDC, Vaccines & Autism."

Dr. William Thompson and the 2004 CDC study

In 2010, Dr. Wakefield's research was found "dishonest" by the UK's General Medical Council. His career was ruined and his name discredited, as the Council barred him and the co-author of the study from practicing medicine. Although he issued challenges to his accusers to debate him in the media, he was of course ignored. Until now.

On August 27, 2014, Dr. William Thompson, who was and remains a scientist at the CDC, hired a whistleblower attorney to make a major statement about the 2004 CDC studyregarding vaccines and autism. As expected, the mainstream media paid little attention to the claim.

Nevertheless, after being secretly recorded by a Dr. Brian Hooker, Dr. Thompson declaredthat he regrets omitting "statistically significant information" in the 2004 article published by the journal Pediatrics. He continued by adding that this data suggested an "increased risk for autism" in African American males who received the vaccine before the age of three. As it was later discovered in the official documents that Dr. Thompson handed over to Congress, evidence about the link between the MMR vaccine and autism was not only omitted but also destroyed by the participating scientists.

When journalist Ben Swann finally managed to get a hold of these documents from congressman Bill Posey, he was joined by other journalists, doctors and CDC specialists in creating a comprehensive documentary on Dr. Thompson's claim, which you can watch here.

The CDC response and interpretation of the study

According to the official statement published by the CDC in response to Dr. Thompson's claims, the 2004 CDC study revealed that vaccination between 24 and 36 months of age was slightly more common among children with autism. This association was most relevant among children aged three to five. However, the authors of the report claimed it was not evidence of a link between the MMR vaccine and a higher risk of autism.

Instead, they assumed that the statistics reflected "immunization requirements for preschool special education program attendance in children with autism." In other words, the CDC claimed that an increased rate of autism among children who received the MMR vaccine before age three was not a case of vaccine injury. According to them, the statistics just appeared this way because children with autism were more likely to be vaccinated before entering a special education program.

Doubt persists among protesters in Atlanta

All of a sudden, it seems that the career of Dr. Andrew Wakefield was buried into the ground for no other reason than scientific curiosity and honesty, as new evidence suggests that he might have had serious reasons for concern regarding the MMR vaccine. Is the CDC, the media or the public going to apologize? No. On the contrary, more studies claiming the absolute safety of vaccines will flourish to cover up previous leaks.

On October 23, 2015, more than 100 protesters gathered in front of the CDC headquarters in Atlanta to demand answers about vaccines. But with all these controversies covered up by the CDC in the past, how much honesty can the people really expect?

Monday, 8 February 2016

Thou shalt call His name Jesus


C H Spurgeon’s Morning Devotional for 8th February

"Thou shalt call His name Jesus."

Matthew 1:21

When a person is dear, everything connected with him becomes dear for his sake. Thus, so precious is the person of the Lord Jesus in the estimation of all true believers, that everything about Him they consider to be inestimable beyond all price. "All Thy garments smell of myrrh, and aloes, and cassia," said David, as if the very vestments of the Saviour were so sweetened by His person that he could not but love them. Certain it is, that there is not a spot where that hallowed foot hath trodden-there is not a word which those blessed lips have uttered-nor a thought which His loving Word has revealed-which is not to us precious beyond all price. And this is true of the names of Christ-they are all sweet in the believer's ear. Whether He be called the Husband of the Church, her Bridegroom, her Friend; whether He be styled the Lamb slain from the foundation of the world-the King, the Prophet, or the Priest-every title of our Master-Shiloh, Emmanuel, Wonderful, the Mighty Counsellor-every name is like the honeycomb dropping with honey, and luscious are the drops that distil from it. But if there be one name sweeter than another in the believer's ear, it is the name of Jesus. Jesus! it is the name which moves the harps of heaven to melody. Jesus! the life of all our joys. If there be one name more charming, more precious than another, it is this name. It is woven into the very warp and woof of our psalmody. Many of our hymns begin with it, and scarcely any, that are good for anything, end without it. It is the sum total of all delights. It is the music with which the bells of heaven ring; a song in a word; an ocean for comprehension, although a drop for brevity; a matchless oratorio in two syllables; a gathering up of the hallelujahs of eternity in five letters.

"Jesus, I love Thy charming name,
'Tis music to mine ear."

Monday, 1 February 2016

The Scandal Of The £5M PACE Trial For ME: What Can Be Done?


'The PACE study is claimed to have negative impact on the way patients are perceived by society'

Over 11,000 ME/CFS patients have signed a petition calling for an independent review of the PACE Trial.

The PACE Trial is a £5 million study promoting the view that ME/CFS patients can recover if they increase their physical activity, claiming that “fear of activity” has fierce negative impact on patients. However, there’s plenty of evidence suggesting otherwise.

Dr Ronald Davis of Stanford University said: “I’m shocked that the Lancet published it… The PACE study has so many flaws and there are so many questions you’d want to ask that I don’t understand how it got through any kind of peer review.”

Even worse, the PACE study is claimed to have negative impact on the way patients are perceived by society and treated in medical practice.

Jo-Anne Dobson MLA is set to join Hope 4 Me & Fibro Northern Ireland in an event titled: The Scandal Of The £5M PACE Trial For ME: What Can Be Done? This exciting presentation, delivered by James C. Coyne PhD, will discuss opposition towards the trial and involve a question and answer session.

James C. Coyne is a professor of psychology at the University of Pennsylvania whose main principle of research has been the coping process in cancer patients and the testing of interventions aimed at affecting these individuals’ wellbeing. He is known for delivering lively lectures that combine science with insight and tenacity.

James has previously criticised positive psychology research that claims a correlation between positive thinking and the progression of cancer and advocates good science and ethical conduct towards patients.

He described himself as: “Irreverent socially concious Clinical Health Psychologist sceptical about hype and hokum in science and medicine and their media representations.”

James and Hope 4 ME & Fibro Northern Ireland are hoping to advocate the importance of science and scientific accuracy when it comes to patient care at this moving and enlightening event.

The professional event is taking place at Stormont Buildings Room 115 on Tuesday 9 February 2016 at 6:30pm.

The open event is taking place at Belfast Castle on Saturday 7 February 2016 3 – 5pm

To book email: hope4mefibro@outlook.com